The effect of age on the response to the pneumococcal polysaccharide vaccine

Hyunju Lee, Moon H. Nahm, Kyung Hyo Kim

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Background: Streptococcus pneumoniae is a leading cause of morbidity and mortality in the elderly. To prevent invasive pneumococcal diseases, the 23-valent pneumococcal polysaccharide vaccine (PPV) is recommended in subjects over 65 years of age. Although it has been reported to provide approximately 50-80% protection against invasive disease in the general elderly population, there is still controversy as to the effectiveness of the PPV in the elderly.Methods: To evaluate the immune response to the pneumococcal polysaccharide vaccine in the elderly, samples from young adults and elderly were obtained before and one month after vaccination. The quantitative and qualitative response to the vaccine were measured by the ELISA and opsonophagocytic killing assay for eight vaccine type serotypes (4, 6B, 9V, 14, 18C, 19A, 19F, 23F) and one vaccine-related serotype (6A).Results: The response to the pneumococcal polysaccharide vaccine showed a similar response between adults and elderly when evaluated by the ELISA, however the functional activity of the antibodies elicited after vaccination were lower in the elderly group for more than half of the serotypes evaluated. In comparison of the antibody needed for 1:8 opsonic titer, more antibodies were needed in the elderly for serotypes Pn 4, 19F, 23F and 6A, suggesting the functional activity of antibody detected by the ELISA was lower in the elderly compared with the adult group for these serotypes. As for subjects with an opsonic titer <8 after vaccination, only one subject each for serotypes Pn 4, 9V and 6A were found in the adult group. However, up to 10 (30.3%) of the subjects did not show opsonic activity after vaccination in the elderly group for serotypes Pn 4, 9V, 14, 19A and 6A.Conclusions: Although the amount of antibodies elicited were similar between the two age groups, distinct differences in function were noted. This report highlights the importance of a quantitative and qualitative evaluation of the immunogenic response to the PPV in the elderly age group.Trial registration: This trial is registered with Clinical Registration number NCT00964769.

Original languageEnglish
Article number60
JournalBMC Infectious Diseases
StatePublished - 10 Mar 2010

Bibliographical note

Funding Information:
We thank Carl Frasch at Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD. for providing us with the reference standard 89-SF Source of financial assistance: This work was partially supported by a grant from KFDA 05092-341 to KHK.


Dive into the research topics of 'The effect of age on the response to the pneumococcal polysaccharide vaccine'. Together they form a unique fingerprint.

Cite this